Short Interest Worth Mentioning Today: A Reversal for Sunesis Pharmaceuticals Incorporated (NASDAQ:SNSS) Is Not Near. The Stock Has Rise in Shorts

November 16, 2016 - By Ruchi Gupta   ·   0 Comments

Short Interest Worth Mentioning Today: A Reversal for Sunesis Pharmaceuticals Incorporated (NASDAQ:SNSS) Is Not Near. The Stock Has Rise in Shorts

The stock of Sunesis Pharmaceuticals Incorporated (NASDAQ:SNSS) registered an increase of 27.73% in short interest. SNSS’s total short interest was 115,600 shares in November as published by FINRA. Its up 27.73% from 90,500 shares, reported previously. With 144,100 shares average volume, it will take short sellers 1 days to cover their SNSS’s short positions. The short interest to Sunesis Pharmaceuticals Incorporated’s float is 1.49%. About 6,214 shares traded hands. Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has risen 29.63% since April 14, 2016 and is uptrending. It has outperformed by 24.94% the S&P500.

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $87.06 million. The Firm focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. It currently has negative earnings. The Firm offers QINPREZO , which is a product candidate for the treatment of acute myeloid leukemia (AML).

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Ratings Coverage

Out of 4 analysts covering Sunesis Pharmaceuticals (NASDAQ:SNSS), 1 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 25% are positive. Sunesis Pharmaceuticals has been the topic of 4 analyst reports since July 24, 2015 according to StockzIntelligence Inc. The firm earned “Outperform” rating on Friday, July 29 by Wells Fargo. The stock of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) earned “Market Perform” rating by Cowen & Co on Friday, July 24. TH Capital downgraded Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) rating on Friday, July 24. TH Capital has “Sell” rating and $1 price target. The firm has “Hold” rating given on Friday, July 24 by Cantor Fitzgerald.

SNSS Company Profile

Sunesis Pharmaceuticals, Inc., incorporated on February 10, 1998, is a biopharmaceutical company. The Firm focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Firm offers QINPREZOTM (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company’s other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229.

Another recent and important Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) news was published by Globenewswire.com which published an article titled: “Sunesis Pharmaceuticals Announces Poster Presentation on Preliminary Results …” on September 01, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Ruchi Gupta


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>